|Date:||Wednesday, 23 September (afternoon) & Thursday, 24 September 24 (morning) 2015|
|Organizers:||Rochdi Bouhelal, Novartis
Xavier Leroy, Actelion
Recent advances in GPCR drug discovery G-protein-coupled receptors (GPCRs) represent the largest group of proteins involved in signal transduction of messengers such as neurotransmitters, hormones, light, odorant principles, ions and protons. Due to their location in the cell membrane and a high level of selectivity in agonist recognition, GPCRs are the most successful therapeutic targets in diverse indications such as cardiovascular disease, asthma, cancer, neurological dysfunction and metabolic disorders. Even if GPCRs are amongst the most studied drug targets, the field is nevertheless witnessing an impressive renaissance with the advent of novel approaches to study these proteins in particular the structural elucidation of a large number of GPCRs the past 8 years . The session will be organized as an open forum for scientists interested in GPCRs to discuss most recent advances in the field. Distinguished speakers & leaders in the field from academia, pharma companies and CROs have been invited to share with us their most recent work. The following themes will be addressed: GPCR and disease, GPCR signaling pathways, Impact of GPCR structural biology in drug discovery, GPCR crosstalk , oligomerization and disease, the GPCR interactome, recent GPCR drug discovery: case studies, uncovering novel GPCRs and ligands, novel technologies to study GPCRs. In addition a keynote distinguished speaker from an academia will be invited.